What intact-mass and sequence evidence should appear on a MOTS-c CoA?
Synthetic MOTS-c corresponds to a defined 16-residue sequence. Primary literature and reviews place it in the mitochondrial-derived peptide class (PMID:29983246; PMID:27216708), but a class name cannot establish the identity of a supplied lot. The specification should state the intended sequence, terminal chemistry, any modifications and counterion form.
For the unmodified chain with free N- and C-termini, the average molecular mass is approximately 2174.6 Da. The expected value must be calculated for the actual specified structure. Average and monoisotopic masses are different conventions and must not be compared interchangeably. The CoA or linked analytical report should identify the ionisation method, the mass convention, observed ions, the reported neutral mass where applicable and a justified acceptance window.
For electrospray measurements, assigned charge states and the underlying spectrum help assess the deconvolution. Other ionisation methods can provide valid identity evidence without a multiply charged ladder. Sodium and potassium adducts and possible oxidation products should be considered during interpretation. An approximately +15.995 Da monoisotopic shift is consistent with addition of one oxygen, but does not by itself establish the modified residue or structure.
Intact mass supports consistency with the intended composition; it does not uniquely establish sequence. Tandem-MS reports should state precursor selection, fragmentation method, fragment assignments and coverage. Routine b- and y-ion assignments generally do not distinguish isoleucine from leucine, and incomplete coverage can leave other ambiguities unresolved. Additional evidence should be selected according to the identity risk rather than claiming that one spectrum excludes every alternative.
Humanin is a separate mitochondrial-derived peptide discussed in its own literature (PMID:34534645). A receiving specification should identify MOTS-c specifically, rather than accepting the broader class label as an identity result.
How should related-substances HPLC be read for a 16-residue MOTS-c lot?
Reversed-phase HPLC with ultraviolet detection can characterise the peptide-related impurity profile. A peptide-bond wavelength, commonly around 214 or 220 nm, is often useful; detection at 280 nm can provide complementary information because MOTS-c contains aromatic residues. Suitability depends on the method, matrix and impurities of interest. Detection at 280 nm alone can underrepresent species with weak aromatic absorption.
The CoA should identify the method and report results against the agreed specification. The supporting analytical package should make the column, mobile phases, gradient, detection settings, sample preparation, injection load and integration approach available at a level sufficient for review. Each reportable peak should have an area result and retention-time information, with an assignment where evidence supports one.
Potential impurities include deletion or truncated sequences, incompletely removed protecting groups and oxidation products. Methionine oxidation can alter retention and produce an oxygen-addition mass shift, but an earlier-eluting peak is not automatically methionine sulfoxide. Retention order is method-dependent, and structural assignments require suitable evidence. Light-associated or other oxidation products should likewise be described as proposed unless confirmed.
Area normalisation measures relative detector response among integrated peaks. It does not measure counterion, water or all residual contaminants, and it does not establish a mass fraction unless response-factor assumptions are justified. Co-eluting impurities can also be hidden within the main peak. Where response factors or reference standards are used, their basis should be documented.
System suitability should be appropriate to the method and its intended use. It may include repeatability, sensitivity, peak shape and resolution of a critical pair. Supporting records should link the sample run, chromatogram, peak table and suitability results. Unexplained discrepancies should be investigated before the material is accepted under the laboratory's receiving procedure.
How do peptide content, counterion and Karl Fischer water affect analyte mass?
A headline HPLC area percentage does not establish how much MOTS-c is present in a vial. Lyophilised material can include peptide-related species, counterions, water and residual solvents. The supplier should define whether nominal content means total lyophilised material, total peptide content or an assay of the intended MOTS-c analyte.
Counterion identity and quantity can be measured using suitably qualified methods, such as ion chromatography or appropriate quantitative NMR procedures. Water may be determined by Karl Fischer analysis using a procedure suitable for the sample and expected water level. Residual-solvent testing should be selected according to the manufacturing process and research specification.
The term net peptide content is not enough by itself: request its definition, analytical basis, reporting basis and calculation. A value obtained by subtracting water, counterion and measured residuals can still include peptide impurities or unidentified material. Amino-acid analysis can provide an orthogonal estimate of total peptide content when the hydrolysis and quantification procedure is suitable, but it is not inherently a selective assay of intact MOTS-c.
Do not automatically multiply net peptide content by HPLC area purity and label the result true MOTS-c content. That calculation requires justified detector-response assumptions and consideration of co-elution and unmeasured components. Where an accurate target-analyte amount is important, specify an appropriately qualified assay and reference material.
Compare quotations and CoAs on the same basis. A stated mass of lyophilised cake is not equivalent to the same stated mass of the intended peptide chain. A mass balance can help identify inconsistencies, but its terms must be non-overlapping, reported on compatible bases and interpreted with measurement uncertainty. An unexplained gap warrants investigation; it does not uniquely identify a particular missing component.
Counterion form should be controlled in the material specification. If acetate is specified, request supporting identity and quantitative information appropriate to that requirement. A change to another counterion should be documented and assessed rather than treated as an interchangeable substitution.
Which lot-traceability fields should be checked before an Australian MOTS-c lot enters a study?
Traceability requires an unambiguous, documented link between the supplied vial and the analytical records for its lot. The vial and CoA should carry matching supplier lot identifiers or an explicit, auditable mapping. HPLC sample names, MS filenames and dispatch records may use different identifiers, provided the records reliably connect them to the same lot.
A receiving checklist should include product identity, lot number, nominal content and its basis, CoA identifier and version, relevant manufacture or analysis dates, storage instructions and the supplier's retest or expiry statement where provided. A supplier retest date applies only under its stated conditions and supporting evidence; it does not automatically apply to different receiving-laboratory conditions.
The analytical package should link numerical results, method identifiers, chromatograms, spectra and review or approval records. Formatting differences, abbreviated filenames or an older analysis date are not proof of a failure. Investigate unexplained inconsistencies, missing mappings or evidence that the records belong to a different lot.
Dispatch documentation should support the chain from supplier to recipient. Useful records include a packing list, dispatch date, tracking information and the lot supplied. Local Australian stock can be relevant to purchasing logistics, but neither stock location nor a tracking number establishes analytical quality or a complete chain of custody. Repackaging, relabelling and distributor lot assignments require documented linkage to the originating lot and analytical package.
For multi-vial or mixed-lot orders, every supplied lot should have appropriate documentation. Retain the specification, CoA, supporting analytical records and receiving decision for the institution's required archive period.
How do complementary MS methods distinguish MOTS-c from related peptides?
Mitochondrial-derived peptides are a class, not interchangeable materials. Humanin has a different sequence from MOTS-c and is discussed in separate literature (PMID:34534645). MOTS-c reviews provide background on the defined research analyte (PMID:36233287; PMID:36761202; PMID:36670507); they do not certify a supplied vial.
Intact electrospray MS can show whether the major observed species has a mass consistent with the specified MOTS-c structure. The average mass of approximately 2174.6 Da applies to the unmodified chain with free termini; a monoisotopic result must instead be assessed against the corresponding calculated monoisotopic value. Instrument resolution, calibration, adducts and data processing affect interpretation.
MALDI-TOF may provide complementary intact-mass evidence with different ionisation behaviour. Agreement between two intact-mass methods can strengthen confidence in the mass assignment, but does not resolve sequence alternatives that share the same mass. Different platforms are not automatically independent proof of sequence.
Tandem MS adds sequence-related evidence. Review assigned ions, coverage at both termini and coverage across positions relevant to plausible truncations or substitutions. Routine fragmentation does not generally distinguish leucine from isoleucine. Near-isobaric differences, such as lysine versus glutamine, require adequate resolving power, mass accuracy and informative fragments.
A receiving laboratory can use a qualified LC-MS procedure to compare the supplied lot with an appropriate reference or established acceptance criteria. Retention-time comparisons require controlled conditions, and MS signal intensity should not be treated as an impurity mass percentage without an appropriate quantitative method. The analytical objective is evidence proportionate to the research specification, not a claim that any single technique proves identity and content completely.
How should Australian laboratories qualify a MOTS-c supplier on documentation?
Supplier qualification should begin with the laboratory's intended analytical specification. Request an example documentation package before purchase and confirm that a lot-specific package will accompany the supplied material. Relevant records may include the CoA, related-substances chromatogram and peak table, intact-mass spectrum, sequence evidence where required, counterion and water results, and a clearly defined content measurement.
An example CoA demonstrates a documentation format, not the quality of a future lot. Confirm which methods are used, which results are reported routinely, what supporting records are available and how the supplier manages out-of-specification results and changes. Not every raw-data field must appear on the CoA itself, but essential evidence should be accessible through controlled, linked records.
Compare suppliers against the same acceptance criteria rather than price or an isolated area-purity percentage. Confirm any claimed Australian stock location, dispatch arrangements and lot-specific packing records. These are procurement attributes, not substitutes for analytical evidence. This article does not verify the inventory, performance or documentation of any particular supplier.
Define how changes in synthesis, counterion, packaging, analytical methods or specifications will be communicated. Method changes may require a documented comparability assessment before results from different lots can be treated as equivalent.
Keep purchase orders and inventory descriptions explicit: research use only, not for human or veterinary use, and not for diagnostic procedures. An RUO label does not by itself determine Australian regulatory classification or demonstrate an exemption from applicable requirements. Classification and supply obligations depend on the product's intended purpose, presentation, claims and relevant law; obtain appropriate regulatory advice where necessary.
The cited biological literature provides context for MOTS-c (PMID:36233287; PMID:36761202). It does not substantiate supplier claims, establish therapeutic approval or replace lot-specific analytical evidence.
Order Mots C with documentation
If this guide helped you evaluate Mots C for laboratory work, the next step is documented supply: research-grade stock from Australian warehouses, Express tracked shipping, and batch documentation with every order.
Open the Mots C card on the ClaraScience shop for current stock and add-to-cart, or request wholesale access when you need bulk restocks and tier pricing.
Frequently asked questions
Does a 99 percent HPLC figure prove that a vial contains MOTS-c?
No. HPLC area percentage describes relative detected peak response under a particular method. It does not establish identity, vial content or the absence of co-eluting impurities. Identity needs suitable mass and sequence evidence; water, counterion and content require separate consideration.
What intact mass should a MOTS-c CoA report?
The unmodified 16-residue chain with free N- and C-termini has an average molecular mass of approximately 2174.6 Da. The report should specify the structure, mass convention, observed ions, processing approach and justified acceptance window. A monoisotopic measurement must be compared with the calculated monoisotopic mass, not the average value.
Why do counterion and Karl Fischer water results matter?
Counterion and water contribute to the mass of lyophilised material without being the MOTS-c chain. Measuring them helps interpret the stated content basis. Subtracting these components does not necessarily produce a selective MOTS-c assay because peptide impurities and unidentified residuals may remain.
Which lot-traceability fields must match?
The supplied vial must link unambiguously to the supplier lot and its CoA. Analytical filenames, sample identifiers and dispatch records may differ if a controlled mapping connects them to that lot. Investigate unexplained mismatches rather than requiring every system to use an identical filename or identifier.
How is MOTS-c distinguished analytically from humanin?
They have different sequences and intact masses. Mass spectrometry and suitable sequence evidence can distinguish them, but a mitochondrial-derived peptide class label cannot. The supplied lot should meet a specification for the intended MOTS-c structure.
Does research-use-only labelling establish that MOTS-c is outside TGA requirements?
No. RUO wording is not proof of regulatory classification, approval or exemption. Australian requirements depend on intended purpose, presentation, claims and applicable law. A CoA establishes only the analytical results it reports; it does not establish registration as a medicine or suitability for human or veterinary use.
References
- PMID:29983246 — The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress — Cell Metab — 2018
- PMID:27216708 — MOTS-c: A novel mitochondrial-derived peptide regulating muscle and fat metabolism — Free Radic Biol Med — 2016
- PMID:36233287 — MOTS-c, the Most Recent Mitochondrial Derived Peptide in Human Aging and Age-Related Diseases — Int J Mol Sci — 2022
- PMID:36761202 — MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne) — 2023
- PMID:34534645 — The emerging role of mitochondrial derived peptide humanin in the testis — Biochim Biophys Acta Gen Subj — 2021
- PMID:36670507 — Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging — J Transl Med — 2023
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
